IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs).
IMIDomics has raised €14M across 1 funding round from 4 investors, most recently a round in Jul 2021. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-07-29 | Other | €14M |
| Bristol Myers Squibb,DNS Capital,TAO Capital,The Pritzker Organization |
| View deal → |
